Brain tumors in the older person

Cancer Control

Volumn 7, Issue 6, 2000, Pages 523-538

  Flowers, Alexandra ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; DNA TOPOISOMERASE INHIBITOR; RETINOID; TAMOXIFEN; VINCA ALKALOID;

ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; HUMAN; PREVALENCE;

EID: 0033652686     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480000700604     Document Type: Article

References (159)

1. National survey of patterns of care for brain tumor patients
2. Brain tumors
3. Cancer statistics, 1991
4. Cancer statistics, 1993
5. Relationship of cancer and aging
6. Experts divided over rising incidence of brain tumors
7. Cancer surveillance series [corrected]: Brain and other central nervous system cancers. Recent trends in incidence and mortality
8. Increasing annual incidence of primary malignant brain tumors in the elderly
9. Is brain cancer mortality-increasing in industrial countries?
10. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota
11. Brain tumors in the elderly: Recent trends in a Minnesota cohort study
12. Time trends in incidence of brain and central nervous system cancers in Connecticut
13. Increasing incidence of primary brain tumors in the elderly in Florida
14. Incidence and survival of brain tumors: A population-based study
15. Descriptive epidemiology of cerebral gliomas in France
16. Incidence of primary cancer of the central nervous system in southeastern Netherlands during the period 1980-94: Specialists in neuro-oncology in southeastern Netherlands
17. Increasing incidence of primary malignant brain tumors: Influence of diagnostic methods
18. Increased mortality from brain tumors: A combined outcome of diagnostic technology and change of attitude towards the elderly
19. The age curve of nervous system tumour incidence in adults: Common shape but changing levels by sex, race and geographical location
20. Is the increased incidence of primary malignant brain tumors in the elderly real?
21. Rising primary malignant brain tumor mortality in the elderly: A manifestation of differential survival
22. Brain tumors and the geriatric patient
23. Epidemiology of brain tumors and factors in prognosis
24. Update on brain cancer epidemiology
25. Astrocytoma risk related to job exposure to electric and magnetic fields
26. Nervous system neoplasms and primary malignancies of other sites: The unique association between meningiomas and breast cancer
27. Association of malignant brain tumors and cancers of other sites
28. Glioma arising after radiation therapy for pituitary adenoma: A report of four patients and estimation of risk
29. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme
30. Report of a workshop sponsored by the European Organisation for Research and Treatment of Cancer (EORTC) on the treatment of primary malignant brain tumours
31. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991
32. The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data
33. How to diagnose and manage adult astrocytomas
34. Brain tumors. Part 1
35. Do surgical brain lesions present as isolated dementia? A population-based study
36. Brain imaging in the diagnosis of intracranial neoplasms
37. Perfusion and metabolism in predicting the survival of patients with central gliomas
38. Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme
39. A simplified classification of gliomas
40. Grading of astrocytomas: A simple and reproducible method
41. Grading of gliomas
42. Correlates of survival and the Daumas-Duport grading system for astrocytomas
43. Survival and prognosis of patients with astrocytoma with atypical anaplastic features
44. Mixed oligoastrocytomas: A survival and prognostic factor analysis
45. Prognostic factors for high-grade malignant glioma: Development of a prognostic index. A report of the Medical Research Council Brain Tumor Working Party
46. Prognostic scoring in adult astrocytic tumors using patient age, histopathologic grade and DNA histogram type
47. Neuropathology, cell biology, and newer diagnostic methods
48. Molecular, genetic and biologic aspects of primary brain tumors
49. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma
50. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors
51. Prognostic significance of p53 immunoreactivity in patients with glioma
52. MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
53. PTEN gene mutations are seen in high-grade but not in low-grade gliomas
54. Malignant brain tumors in the elderly
55. Supratentorial low-grade astrocytomas in adults
56. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients
57. Effect of age on treatment decisions in low-grade glioma
58. Therapy and survival of adult patients with intracranial glioma in a defined population
59. Malignant gliomas in older adults with poor prognostic signs: Getting nowhere, and taking a long time to do it
60. Do elderly patients overutilize healthcare resources and benefit less from them than younger patients? A study of patients who underwent craniotomy for treatment of neoplasm
61. Supratentorial malignant glioma in adults: Adjustment of the treatment of 3 groups according to a clinical classification [French]
62. Brain tumors in the elderly
63. Surgery for malignant glioma
64. Resection, biopsy and survival in malignant glial neoplasms: A retrospective study of clinical parameters, therapy and outcome
65. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas
66. The effect of extent of resection on recurrence in patients with low grade cerebral hemispheric gliomas
67. CT prognostic criteria of survival after malignant glioma surgery
68. Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis
69. Brain tumor surgery in geriatric patients: A critical analysis in 44 patients over 80 years
70. Supratentorial anaplastic gliomas in adults: The prognostic importance of extent of resection and prior low-grade glioma
71. Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytomas
72. Use of a frameless, armless stereotactic wand for brain tumor localization with two-dimensional and three-dimensional neuroimaging
73. Radiation therapy of brain tumors
74. Low-grade gliomas: To treat or not to treat? A radiation oncologist's viewpoint
75. The role of radiation therapy in the treatment of astrocytomas
76. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme
77. Malignant supratentorial glioma in the elderly: Is radiotherapy useful?
78. The effect of advanced age on the efficacy of radiation therapy for early breast cancer, local prostate cancer and grade III-IV gliomas
79. Supratentorial malignant glioma: An analysis of radiation therapy in 178 cases
80. Efficacy of radiotherapy for malignant gliomas in elderly patients
81. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme
82. Hypofractionated radiation therapy and concurrent cisplatin in malignant cerebral gliomas: Rapid palliation in low performance status patients
83. Accelerated fractionation radiotherapy for hospitalized glioblastoma multiforme patients with poor prognostic factors
84. Preliminary results of a phase II trial of RSR13 in newly diagnosed GBM
85. Fractionated stereotactic radiation therapy for intracranial tumors
86. Radiotherapy/stereotactic external beam radiotherapy for malignant brain tumours: The Royal Marsden Hospital experience
87. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome
88. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas
89. Survival following interstitial brachytherapy for recurrent malignant glioma
90. Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent tumors
91. Boron neutron capture therapy for murine malignant gliomas
92. Neutron capture therapy for cancer [in Japanese]
93. Therapeutic irradiation and brain injury
94. Radiation effects on cerebral white matter: MR evaluation
95. Radiation necrosis or glioma recurrence: Is computer-assisted stereotactic biopsy useful?
96. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: Neuropsychologic outcome and proposed mechanisms
97. Adult mental deterioration, the main limiting factor in cerebral radiotherapy? [French]
98. Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy
99. Chemotherapy for malignant brain tumors
100. Chemotherapy for malignant gliomas
101. Chemotherapy for brain tumors
102. Resistance to cytostatic drugs at the cellular level
103. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine
104. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
105. Do anticancer agents reach the tumor target in the human brain?
106. The blood-brain barrier: Implications for chemotherapy in brain tumors [French]
107. Chemotherapy of brain tumors
108. Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas
109. Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma
110. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure
111. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas
112. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
113. A randomized study of chemotherapy with procarbazine, vincristine and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4
114. Procarbazine, lomustine and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
115. Low-grade oligodendroglioma responds to chemotherapy
116. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group
117. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: A joint Radiation Therapy Oncology Group and Eastern Cooperative Group Study
118. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
119. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
120. Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme
121. Pre-irradiation chemotherapy in glioma patients with poor prognostic factors
122. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of 'failed' patients
123. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen
124. Cytokines and immunoregulatory molecules in malignant glial neoplasms
125. Chemotherapy and immunotherapy in adult malignant gliomas
126. Retinoids as preventive and therapeutic anticancer agents (Part II)
127. Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells
128. 13-Cis-retinoic acid: A new and potentially effective agent for recurrent malignant astrocytomas
129. Interferon modulates human glioma protein kinase C II
130. Clinical effect of interferon in malignant brain tumours
131. Phase II trial of interferon-beta for treatment of recurrent glioblastoma multiforme
132. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma
133. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma
134. Biologic therapy for brain tumors
135. Reversible osmotic blood-brain barrier disruption in humans: Implications for the chemotherapy of malignant brain tumors
136. Osmotic blood-brain harrier disruption and chemotherapy in the treatment of high grade malignant glioma: Patient series and literature review
137. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas
138. Expanded spectrum of viral therapy in the treatment of nervous system tumors
139. Rapid cytotoxicity with gancyclovir following adenovirus transduction of glioma cells with herpes virus thymidine kinase
140. Immunotoxins and central nervous system neoplasia
141. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia
142. Experimental therapies for malignant gliomas: Targeting the mevalonate pathway of cholesterol synthesis
143. Phenylacetate and related nontoxic differentiation inducers in treatment of prostate, brain and skin cancer
144. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
145. Potentiation of cytotoxic cancer therapies by AGM-1470 (AGM) alone and with other angiogenic antiangiogenic agents
146. Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?
147. Management of metastatic brain tumors: A review
148. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age
149. The results of the radiotherapy of brain metastases in patients at an advanced age [German]
150. Underrepresentation of patients 65 years of age or older in cancer-treatment trials
151. Age influences chemotherapy response in astrocytomas
152. Age-related chemosensitivity of stem cells from human malignant brain tumors
153. Quality of survival in patients with brain gliomas treated with postoperative CCNU and radiation therapy
154. The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors
155. Neurobehavioral disorders in brain tumor patients: Rehabilitation strategies
156. CNS tumors: Supportive management of the patient and family
157. Brain tumors
158. Cancer control and the older person: Issues in treatment